Brookfield Renewable Partners LP (BEP) Is At $35.37 Formed Wedge; Profile of 3 Analysts Covering Motif Bio PLC (LON:MTFB)

August 27, 2017 - By marketbeat

Brookfield Renewable Partners LP (BEP) formed wedge up with $37.14 target or 5.00% above today’s $35.37 share price. Brookfield Renewable Partners LP (BEP) has $5.91 billion valuation. The stock increased 0.23% or $0.08 on August 25, reaching $35.37. About 67,765 shares traded or 7.93% up from the average. Brookfield Renewable Partners LP (NYSE:BEP) has risen 12.26% since August 27, 2016 and is uptrending. It has underperformed by 4.44% the S&P500.

Among 3 analysts covering Motif Bio Plc (LON:MTFB), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Motif Bio Plc had 63 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was maintained by Northland Capital on Tuesday, November 24 with “Buy”. The stock of Motif Bio PLC (LON:MTFB) earned “Buy” rating by Northland Capital on Wednesday, January 18. The stock has “Buy” rating by Northland Capital on Wednesday, January 6. The stock of Motif Bio PLC (LON:MTFB) earned “Speculative Buy” rating by Beaufort Securities on Wednesday, November 25. The stock of Motif Bio PLC (LON:MTFB) has “Buy” rating given on Monday, November 21 by Northland Capital. The firm has “Speculative Buy” rating by Beaufort Securities given on Wednesday, December 16. Beaufort Securities maintained Motif Bio PLC (LON:MTFB) on Thursday, July 23 with “Speculative Buy” rating. The stock of Motif Bio PLC (LON:MTFB) earned “Speculative Buy” rating by Beaufort Securities on Thursday, November 12. The stock of Motif Bio PLC (LON:MTFB) has “Buy” rating given on Wednesday, November 11 by Northland Capital. The stock has “Buy” rating by Northland Capital on Friday, May 5. See Motif Bio PLC (LON:MTFB) latest ratings:

24/08/2017 Broker: FinnCap Rating: Buy Old Target: GBX 100.00 Maintain
09/08/2017 Broker: Northland Capital Rating: Buy Maintain
09/08/2017 Broker: FinnCap Rating: Buy Old Target: GBX 100.00 New Target: GBX 100.00 Maintain
06/07/2017 Broker: Northland Capital Rating: Buy Maintain
07/06/2017 Broker: FinnCap Rating: Buy Old Target: GBX 125.00 New Target: GBX 100.00 Maintain
05/06/2017 Broker: Northland Capital Rating: Buy Maintain
05/06/2017 Broker: Beaufort Securities Rating: Speculative Buy Old Target: GBX 110.00 New Target: GBX 110.00 Maintain
02/06/2017 Broker: Northland Capital Rating: Corporate Maintain
30/05/2017 Broker: FinnCap Rating: Buy Old Target: GBX 125.00 New Target: GBX 125.00 Maintain
10/05/2017 Broker: Northland Capital Rating: Buy Old Target: GBX 90.00 New Target: GBX 90.00 Maintain

It closed at GBX 27 lastly. It is down 0.00% since August 27, 2016 and is . It has underperformed by 16.70% the S&P500.

Motif Bio plc is a clinical-stage biopharmaceutical company. The company has market cap of 70.58 million GBP. The Firm is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It currently has negative earnings. It operates in the development and commercialization of pharmaceutical formulations segment.

Among 8 analysts covering Brookfield Renewable Energy Partners (NYSE:BEP), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 25% are positive. Brookfield Renewable Energy Partners had 17 analyst reports since August 19, 2015 according to SRatingsIntel. The rating was initiated by TD Securities with “Buy” on Wednesday, July 12. The rating was upgraded by Zacks on Wednesday, August 19 to “Hold”. The stock of Brookfield Renewable Partners LP (NYSE:BEP) has “Outperform” rating given on Monday, June 13 by BMO Capital Markets. The firm has “Hold” rating by Macquarie Research given on Wednesday, June 28. The stock has “Buy” rating by Desjardins Securities on Thursday, January 14. Barclays Capital downgraded it to “Equal-Weight” rating and $30 target in Monday, October 12 report. The stock has “Hold” rating by RBC Capital Markets on Friday, August 4. BMO Capital Markets maintained the shares of BEP in report on Tuesday, July 11 with “Hold” rating. The stock has “Equal-Weight” rating by Barclays Capital on Monday, August 7. The stock has “Buy” rating by Guggenheim on Wednesday, July 20.